CVS Investor Day and the IRA
Cordavis and the Battle of Biosimilars
I was digging deep into the Inflation Reduction Act (IRA) over the holidays and came across some of the information on driving biosimilar utilization into the market as a way to cut costs in US healthcare. Then rewind a few weeks while listening to the CVS earnings (along with investor day yesterday) and they mentioned their bullish posture on Cordavis …
Keep reading with a 7-day free trial
Subscribe to The Healthcare Economy to keep reading this post and get 7 days of free access to the full post archives.